Lyell Immunopharma (LYEL) Competitors $0.59 -0.05 (-7.90%) (As of 04:00 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LYEL vs. IMNM, KURA, KROS, TYRA, ERAS, CRON, EOLS, DNTH, RAPP, and AUTLShould you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Erasca (ERAS), Cronos Group (CRON), Evolus (EOLS), Dianthus Therapeutics (DNTH), Rapport Therapeutics (RAPP), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Lyell Immunopharma vs. Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Erasca Cronos Group Evolus Dianthus Therapeutics Rapport Therapeutics Autolus Therapeutics Immunome (NASDAQ:IMNM) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Which has better valuation & earnings, IMNM or LYEL? Immunome has higher revenue and earnings than Lyell Immunopharma. Immunome is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$10.13M73.58-$106.81M-$8.11-1.47Lyell Immunopharma$63K2,996.75-$234.63M-$0.79-0.82 Is IMNM or LYEL more profitable? Immunome has a net margin of -3,014.59% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-3,014.59% -48.63% -41.62% Lyell Immunopharma -323,792.09%-34.64%-30.02% Which has more risk & volatility, IMNM or LYEL? Immunome has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.45, meaning that its stock price is 145% less volatile than the S&P 500. Does the media refer more to IMNM or LYEL? In the previous week, Immunome had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for Immunome and 2 mentions for Lyell Immunopharma. Immunome's average media sentiment score of 1.19 beat Lyell Immunopharma's score of 0.67 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IMNM or LYEL? Immunome presently has a consensus target price of $28.83, indicating a potential upside of 141.49%. Lyell Immunopharma has a consensus target price of $1.00, indicating a potential upside of 54.75%. Given Immunome's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunome is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the MarketBeat Community prefer IMNM or LYEL? Immunome received 17 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 73.81% of users gave Immunome an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformImmunomeOutperform Votes3173.81% Underperform Votes1126.19% Lyell ImmunopharmaOutperform Votes1448.28% Underperform Votes1551.72% Do insiders and institutionals hold more shares of IMNM or LYEL? 44.6% of Immunome shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 8.6% of Immunome shares are held by company insiders. Comparatively, 25.1% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryImmunome beats Lyell Immunopharma on 11 of the 18 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYEL vs. The Competition Export to ExcelMetricLyell ImmunopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$173.81M$6.73B$5.06B$8.95BDividend YieldN/A3.06%4.83%4.06%P/E Ratio-0.7510.56133.9117.01Price / Sales2,758.84267.801,148.99126.86Price / CashN/A57.1640.5637.95Price / Book0.235.214.764.71Net Income-$234.63M$151.85M$118.62M$225.30M7 Day Performance-30.01%-7.55%12.28%-3.40%1 Month Performance-46.41%-1.03%12.40%4.80%1 Year Performance-69.49%12.14%31.63%18.86% Lyell Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYELLyell Immunopharma2.3126 of 5 stars$0.59-7.9%$1.00+68.1%-66.4%$173.81M$63,000.00-0.75270IMNMImmunome2.6346 of 5 stars$12.43-1.2%$28.83+132.0%+59.4%$775.84M$10.13M-1.5540Short Interest ↓Positive NewsKURAKura Oncology4.5736 of 5 stars$9.94+3.2%$29.38+195.5%-20.8%$772.93MN/A-4.08142KROSKeros Therapeutics3.0921 of 5 stars$18.80-0.2%$81.33+332.6%-44.6%$761.53M$651,000.00-3.61100Analyst DowngradeNews CoverageHigh Trading VolumeTYRATyra Biosciences2.1888 of 5 stars$14.90-0.3%$31.00+108.1%+12.7%$753.94MN/A-9.2820ERASErasca2.6129 of 5 stars$2.62+2.3%$5.90+125.2%+40.6%$740.75MN/A-3.08126Positive NewsGap UpCRONCronos Group2.3543 of 5 stars$1.94+0.3%$3.00+55.0%+1.0%$739.75M$87.24M-15.19356Short Interest ↓News CoveragePositive NewsEOLSEvolus3.9289 of 5 stars$11.51flat$23.00+99.8%+18.5%$728.81M$202.09M-12.73170Positive NewsDNTHDianthus Therapeutics1.6778 of 5 stars$24.31+2.1%$46.43+91.0%+235.7%$719.58M$2.83M-9.5280Positive NewsRAPPRapport Therapeutics1.8607 of 5 stars$19.34+3.0%$35.00+81.0%N/A$707.46MN/A0.00N/ANews CoveragePositive NewsAUTLAutolus Therapeutics3.0234 of 5 stars$2.63+5.6%$10.40+295.4%-50.3%$699.82M$1.70M-2.06330 Related Companies and Tools Related Companies IMNM Alternatives KURA Alternatives KROS Alternatives TYRA Alternatives ERAS Alternatives CRON Alternatives EOLS Alternatives DNTH Alternatives RAPP Alternatives AUTL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LYEL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectCrypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
